<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109254">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895764</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI12-ED-COMARIS</org_study_id>
    <secondary_id>2012-004939-23</secondary_id>
    <secondary_id>A130042-32</secondary_id>
    <secondary_id>2012-R41</secondary_id>
    <nct_id>NCT01895764</nct_id>
  </id_info>
  <brief_title>Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)</brief_title>
  <acronym>COMARIS</acronym>
  <official_title>Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if association of methotrexate with adalimumab
      leads to decrease immunogenicity beside adalimumab alone in Ankylosing Spondylitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>presence or absence of antibodies against adalimumab</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of T and B cells concentrations.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of &quot;APRIL&quot; and &quot;TNF alpha&quot; concentrations</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab 40mg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab + Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adalimumab 40mg every 2 weeks and methotrexate 10mg per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_label>Adalimumab + Methotrexate</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26</description>
    <arm_group_label>Adalimumab + Methotrexate</arm_group_label>
    <other_name>Metoject</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject 18 years of age or older

          -  Able and willing to give written informed consent and to comply with the requirements
             of the study protocol

          -  Subject met the definition of Ankylosing Spondylitis (AS) based on ASAS Criteria

          -  Subject with active AS, has had an inadequate response, an intolerance or an to one
             or more nonsteroidal anti-inflammatory drugs

        Exclusion Criteria:

          -  Previous adalimumab treatment or previous treatment with more than one anti TNF alpha
             therapy.

          -  Previous methotrexate treatment, not stopped 3 month before inclusion

          -  Surgery scheduled during study

          -  Female subject without method of contraception

          -  Contraindication to adalimumab or methotrexate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie DUCOURAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de TOURS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie DUCOURAU, MD</last_name>
    <phone>02.47.47.59.17</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.ducourau@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoann DESVIGNES</last_name>
    <phone>02.47.47.46.32</phone>
    <phone_ext>+33</phone_ext>
    <email>yoann.desvignes@med.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rhumatologie, CH de BLOIS</name>
      <address>
        <city>Blois</city>
        <zip>41000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabienne LE GUILCHARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CHRU de BREST</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valérie DEVAUCHELLE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CHD LA ROCHE SUR YON</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grégoire CORMIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CHR du MANS</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuelle DERNIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CHRU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoit LE GOFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie / IPROS, CHR d'ORLEANS</name>
      <address>
        <city>Orleans</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carine SALLIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CHRU de POITIERS</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth SOLAU-GERVAIS, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CHRU de RENNES</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleth PERDRIGER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CH de SAINT BRIEUC</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine MARTIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine polyvalente, CH de SAINT NAZAIRE</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas ARMINGEAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhumatologie, CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie DUCOURAU, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Denis MULLEMAN, MD-PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Denis MULLEMAN, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ankylosing spondylitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
